Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Members; Adds Depth of Knowledge, Experience to Strengthen Company’s Vision
- Appointments signify POAI’s commitment to aligning board’s expertise with company’s strategic vision
- Board members to support development, commercialization of unique offering that improves outcomes for oncology patients, value to shareholders
- New appointments effective immediately
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, announced the appointment of three new highly qualified individuals to its board of directors (http://nnw.fm/4yXBn). The three new board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring with them more than a century of invaluable experience in business development, marketing and financial expertise in the life-sciences space.
“These appointments signify our absolute commitment to aligning our Board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value to our shareholders,” said POAI CEO Dr. Carl Schwartz. “Each of these members brings a wealth of knowledge, experience and thought leadership that will be highly valuable as we execute our plans to develop and market AI-based predictive models that leverage our unique tumor bank.”
Bringing with her more than 25 years of business development and marketing experience in the life sciences market, Chung-Welch has built a strong record of national and global accomplishments. She currently works as an independent consultant in the life-science sector, with a targeted focus on the research product/tools market.
She has served as director of business development at both Cell Signaling Technology and Thermo Fisher Scientific as well as technical marketing manager for Fisher Scientific. In those roles, she conceptualized, launched and managed products and services in the laboratory, medical, biotech/pharma, academic and government markets. Chung-Welch earned a PhD in vascular physiology and cell biology from Boston University.
As a certified CPA and experienced board member for several international organizations, Nuzum brings with him almost 50 years of operations, executive leadership and military experience across a broad spectrum of enterprises. He currently provides project-based financial consulting services to companies such as McKesson, BioMarin, AutoDesk and Squire Patton Boggs.
In addition, he co-founded and served as CFO for two companies: Tyburn Group, a financial services company that creates and delivers prepaid payroll and general-purpose card programs, and SVC Financials Services, one of the first companies in the field to integrate a mobile money solution for global distribution. As CFO of Loomis Fargo & Co. for almost 20 years, Nuzum transformed the company from a small Seattle-based armored car company to an international security and diversified-transportation company with more than $350 million in revenue and over 3,000 employees. An Army veteran and recipient of the Bronze Star and Army Commendation Medal, Nuzum served all over the world and as an intelligence officer in Washington, DC.
As an innovator and entrepreneur, St. Clair has more than 30 years of hands-on experience in growing companies across a variety of markets. His broad experience includes executive leadership, strategic planning, compliance, reimbursement and revenue integrity and cycle management in the health systems and biomedical sectors. St. Clair is founder and a managing member of SunStone Consulting. Prior to that, he worked as a national vice president for three different organizations — CGI, ImrGlobal and Orion Consulting — and as a national director for Coopers & Lybrand.
The new appointments are effective immediately. POAI’s board of directors includes seven members, with each new board member serving as an independent director as defined by Nasdaq Corporate Governance rules.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information about the company, visit www.Predictive-Oncology.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Appointments signify POAI’s commitment to aligning board’s expertise with company’s strategic vision
- Board members to support development, commercialization of unique offering that improves outcomes for oncology patients, value to shareholders
- New appointments effective immediately
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, announced the appointment of three new highly qualified individuals to its board of directors (http://nnw.fm/4yXBn). The three new board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring with them more than a century of invaluable experience in business development, marketing and financial expertise in the life-sciences space.
“These appointments signify our absolute commitment to aligning our Board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value to our shareholders,” said POAI CEO Dr. Carl Schwartz. “Each of these members brings a wealth of knowledge, experience and thought leadership that will be highly valuable as we execute our plans to develop and market AI-based predictive models that leverage our unique tumor bank.”
Bringing with her more than 25 years of business development and marketing experience in the life sciences market, Chung-Welch has built a strong record of national and global accomplishments. She currently works as an independent consultant in the life-science sector, with a targeted focus on the research product/tools market.
She has served as director of business development at both Cell Signaling Technology and Thermo Fisher Scientific as well as technical marketing manager for Fisher Scientific. In those roles, she conceptualized, launched and managed products and services in the laboratory, medical, biotech/pharma, academic and government markets. Chung-Welch earned a PhD in vascular physiology and cell biology from Boston University.
As a certified CPA and experienced board member for several international organizations, Nuzum brings with him almost 50 years of operations, executive leadership and military experience across a broad spectrum of enterprises. He currently provides project-based financial consulting services to companies such as McKesson, BioMarin, AutoDesk and Squire Patton Boggs.
In addition, he co-founded and served as CFO for two companies: Tyburn Group, a financial services company that creates and delivers prepaid payroll and general-purpose card programs, and SVC Financials Services, one of the first companies in the field to integrate a mobile money solution for global distribution. As CFO of Loomis Fargo & Co. for almost 20 years, Nuzum transformed the company from a small Seattle-based armored car company to an international security and diversified-transportation company with more than $350 million in revenue and over 3,000 employees. An Army veteran and recipient of the Bronze Star and Army Commendation Medal, Nuzum served all over the world and as an intelligence officer in Washington, DC.
As an innovator and entrepreneur, St. Clair has more than 30 years of hands-on experience in growing companies across a variety of markets. His broad experience includes executive leadership, strategic planning, compliance, reimbursement and revenue integrity and cycle management in the health systems and biomedical sectors. St. Clair is founder and a managing member of SunStone Consulting. Prior to that, he worked as a national vice president for three different organizations — CGI, ImrGlobal and Orion Consulting — and as a national director for Coopers & Lybrand.
The new appointments are effective immediately. POAI’s board of directors includes seven members, with each new board member serving as an independent director as defined by Nasdaq Corporate Governance rules.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information about the company, visit www.Predictive-Oncology.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
